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ABSTRACT
Background: Pulmonary hypertension (PH) is a progressive disorder of the pulmonary circulation,
associated with diverse medical conditions. Exercise limitation is the most prominent symptom in
PH. Exercise capacity, commonly assessed through a six-minute walk test (6MWT), correlates with
both functional status and survival in PH. Few studies have analysed the relation between
respiratory function and exercise limitation. Therefore, we investigated the relationship between
resting pulmonary function, exercise capacity, and exertional desaturation, assessed through the
6MWT, in unselected PH patients.
Methods: Fifty consecutive patients with PH diagnosis, referred for pulmonary function testing
(lung volume, spirometry, and diffusing capacity for carbon monoxide (DLCO)) and 6MWT, were
recruited at Molinette University Hospital, Turin.
Results: The majority of the patients (54%) had PH due to left heart disease. Airway obstruction
(FEV1/VC-ratio < 0.7) was found in 46% of the patients and they performed significantly worse in
the 6MWT than unobstructed patients (307 m vs. 377 m). Patients with PH due to left heart
disease also performed significantly poorer 6MWT when airway obstruction was present (305 m
vs. 389 m). Twenty-two patients (44%) presented exertional desaturation upon 6MWT. Lower
DLCO divided by the alveolar volume (DLCO/VA), FEV1/VC-ratios and resting PaO2-values were
significantly correlated with exertional desaturation after adjustments for age, sex, BMI, and
smoking habits. DLCO/VA was the main determinant of exertional desaturation in a stepwise
regression model.
Conclusions: Spirometric parameters of airway obstruction were related to walk distance and
exercise-induced desaturation in PH patients. This suggests a place for spirometry in clinical
monitoring of PH patients.
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Pulmonary hypertension (PH) is a diverse group of entities
affecting the pulmonary circulation and is defined by a
resting mean pulmonary arterial pressure over 25 mmHg,
confirmed by right heart catheterization [1,2]. A WHO
classification divides PH into five major subtypes based on
pathological, pathophysiological, and therapeutic charac-
teristics: (1) pulmonary arterial hypertension (PAH); (2)
PH due to left heart disease; (3) PH due to interstitial lung
disease and/or hypoxia (PH-ILD); (4) chronic throm-
boembolic PH (CTEPH); and (5) PH with unclear and/
or multifactorial mechanisms [1].
While the abnormalities of the cardiovascular system in
PH are well described, it is unclear to what extent the
respiratory system is affected [3]. The abnormal pulmon-
ary vessels could affect the function of the adjacent airways
and lung parenchyma and contribute to symptoms.
Contradictory results exist regarding the presence of air-
way obstruction in PAH, with studies reporting no differ-
ences [4,5], or a lower ratio of forced expiratory volume in
1 sec to forced vital capacity (FEV1/VC) compared with
controls [6,7]. Restrictive pulmonary function pattern can
be found in up to 50% of PAH patients and is also found in
patients with PH due to left heart disease [8]. The most
consistent lung function limitation in PH is an abnormal
gas transfer assessed through diffusing capacity for carbon
monoxide (DLCO) [3,4,9,10], which is found in the large
majority of PH patients. The alveolo-capillary membrane
function can also be assessed by adjusting the diffusing
capacity for the ‘accessible’ alveolar volume (DLCO/VA)
[11]. However, similar value of DLCO and DLCO/VAwas
found as predictor for pulmonary gas exchange [12]. Since
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PH can have diverse underlying causes, the reducedDLCO
may be attributed to different essential mechanisms such
as ventilation-perfusionmismatch, thickening of the alveo-
lar capillary membrane due to endothelial cell prolifera-
tion, reductions in pulmonary capillary blood volume, low
cardiac output, hypoxic vasoconstriction, and right heart
dysfunction [13]. Even though reduced DLCO is a com-
mon finding in PH, it is not included in the risk stratifica-
tion protocols of PH patients [14], and the clinical
significance of DLCO impairment in PH is less obvious
[15,16]. Furthermore, the relation of the functional limita-
tion, assessed through six-minute walk distance (6MWD),
and extensive lung function, with measurements of spiro-
metry, lung volumes, and DLCO, have not been thor-
oughly characterized in patients with PH.
Exertional dyspnoea and exercise intolerance are the
main clinical findings in PH. These have been attributed
to decreased cardiac output, under-perfusion of the alveoli
caused by remodelled small pulmonary arteries, hyperven-
tilation, and respiratory and peripheral muscle dysfunction
[17–19]. Exercise capacity correlates with survival and
functional status in PH [20,21]. As a result, exercise capa-
city, commonly assessed through the six-minute walk test
(6MWT), has been amandatory, if not a primary, outcome
measure in the majority of the recent clinical trials in PH
[22].Moreover, the 6MWTalso evaluates exercise-induced
oxygen desaturation, known to occur often in patients with
pulmonary vascular disease [23]. However, few studies
have attempted to explore the relationship between pul-
monary function and exertional desaturation in PH
patients [24].
The aim of the present study was to investigate the
relationship of resting pulmonary function including
DLCO with exercise capacity and exertional desaturation,




A total of 50 consecutive patients visiting, during the period
2012–2013, the Pulmonary Function Testing Unit of
Molinette University Hospital, Turin, Italy, upon referral
from the cardiology consultant for pulmonary evaluation,
which included pulmonary function test and six-minute
walk test, were included in the study. These patients were
previously diagnosed with pulmonary hypertension, based
upon hemodynamic data attained by right heart catheter-
ization (mean pulmonary arterial pressure above 25 mm
Hg), and were subsequently divided into PH subgroups
according to guidelines [25]. Information on comorbidities
listed in Table 1 was extracted from the medical journals.
Heart disease was defined as ischemic disease/valvular dis-
ease/grow-up congenital heart disease/cardiomyopathy/
left ventricular diastolic dysfunction. Among PH group I
patients, two had ongoing treatment with bosentan and
two had ongoing treatment with sildenafil.
Pulmonary function tests
Spirometry was performed using a computerized water-
sealed Stead-Wells spirometer (Biomedin, Padua, Italy).
Lung volumes were obtained through using the Baires
System (Biomedin, Padua, Italy) andHeliumdilution tech-
nique. All lung function testing was performed following
the standards outlined by ATS/ERS [26,27]. Reference
values were used in accordance with standardized lung
function testing [28] and lung function parameters were
expressed as both absolute values and % of predicted
values.
Pre-bronchodilatory spirometry was used for all
subjects with the exception of patients with previously
diagnosed COPD (n = 10), for whom post-bronchodi-
latory values were used.
Gas transfer for carbon monoxide (DLCO) was
measured with the single-breath technique, using the
Baires System (Biomedin, Padua, Italy) with a gas mix-
ture of 0.3% CO, 10% helium, and balance air.
Table 1. Patient characteristics.
Variables All subjects (n = 50)
Female sex 26 (52%)
Age (years) 62.4 ± 11.8
BMI (kg/m2) 25.5 ± 6.2
Smoking habit
Never smoker 20 (42%)
Ex-smoker 4 (8%)
Current smoker 24 (50%)
PH
Group 1 10 (20%)
Group 2 27 (54%)
Group 3 4 (8%)
Group 4 6 (12%)




Pulmonary fibrosis 3 (6%)
Heart disease # 33 (66 %)
Diabetes 13 (26%)
History of cancer 16 (32%)
Values presented as means ± SD or N (%).
BMI = body mass index; PH = pulmonary hypertension; PH group 1 =
pulmonary arterial hypertension; PH group 2 = PH due to left heart disease;
PH group 3 = PH due to interstitial lung disease and/or hypoxia; PH group 4
= PH due to chronic thromboembolism; PH group 5 = PH with unclear and/
or multifactorial mechanisms; LTOT = long-term oxygen therapy; OSAS =
obstructive sleep apnoea syndrome; COPD = Chronic obstructive pulmonary
disease.
# Description of heart disease was following: 11 patients suffered from
ischemic heart disease, 11 patients had valvular heart disease, 5 patients
had dilated cardiomyopathy and 6 patients showed signs of left ventricular
diastolic dysfunction, 3 patients had congenital heart disease.
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The lung function parameters used in the present ana-
lyses were forced expiratory volume in 1 sec (FEV1), peak
expiratory flow (PEF), forced expiratory flow at 25–75% of
vital capacity (FEF25–75) and Vital Capacity (VC) from
spirometry, total lung capacity (TLC), residual volume
(RV), RV/TLC-ratio, DLCO, and DLCO divided by the
alveolar volume (DLCO/VA).
Six-minute walk test
Six-minute walk tests were conducted in accordance
with guidelines [29]. Briefly, walk distance was mea-
sured after the subjects had walked as far as possible in
6 min in a 30 m corridor at sea level. Peripheral
capillary oxygen saturation (SpO2) and heart rate
were measured before and immediately after the
6MWT using a pulse oximeter with a finger sensor.
Reference values according to Chetta et al. [30] were
used and 6MWD was expressed as both absolute value
and % of predicted value.
Acquisition of baseline SpO2 was obtained when
patients were relaxed and in the sitting position.
Exercise-induced oxygen desaturation was defined in
accordance with the Royal College of Physicians’ guide-
lines [31] as a minimum of 5% reduction between
arterial oxygen saturation measured through pulse oxi-
metry pre- and post-test.
Arterial blood gases (ABG)
Partial arterial pressure of carbon dioxide (PaCO2) and
partial arterial pressure of oxygen (PaO2) were mea-
sured using the GEM 4000 Premiere analyser
(Instrumentation Laboratory, Lexington, USA).
Statistical analyses
Statistical analyses were performed using a computer
software program (STATA 12.1, StataCorp, College
Station, TX, USA). Mean ± standard deviation (SD)
was used to present the descriptive statistics.
Simple linear regression was used to analyse the
relation between different single lung function para-
meters and 6MWD. These relations were tested for
consistency in a multiple linear regression model that
included sex, age, BMI, and smoking habits, in addition
to the lung function parameters. Finally, a stepwise
regression model including arterial blood gases, resting
SpO2, all lung function parameters which showed sta-
tistically significant correlation to 6MWD, sex, age,
BMI, and smoking habits was used to determine the
most important predictors of 6MWD.
Unpaired t-tests were used to compare 6MWD in
patients with normal and decreased lung function, respec-
tively, when such grouping was done. Decreased lung
function was defined as a value below 80% predicted,
with the exception of the FEV1/VC-ratio, for which it
was defined as an absolute value below 0.7 (and for specific
subanalyses as a value below the lower limit of nor-
mal (LLN)).
A p value <0.05 was considered as statistically
significant.
Ethics
The trial was reviewed and approved by the Interaziendale
Ethical Review Board in Turin (reference number: 370/
378/70/2011, approved 28 September 2011). All patients
gave written informed consent to the study.
Results
Population characteristics
Patient characteristics for the whole group at inclusion
are presented in Table 1. The majority of the patients
were categorized as PH groups 1 and 2 according to the
WHO classification and four patients (8%) were diag-
nosed to have developed PH due to underlying lung
diseases. Most patients were either ex- or current smo-
kers. The majority (69%) of the investigated subjects
suffered from heart disease. One-fifth of the subjects
had a medical record of COPD diagnosis.
Lung function parameters are presented in Table 2.
Reduced DLCO was found in 46 patients (92%) and 5
Table 2. Indices of lung function, respiratory parameters and
6MWD.
Variables Absolute values Percent predicted
FEV1 (L) 2.1 ± 0.7 76.4 ± 19.4
VC (L) 2.9 ± 1.0 81.7 ± 19.9
FEV1/VC (%) 70.0 ± 9.3 -
FEF25-75 (L/s) 1.6 ± 1.0 53.5 ± 29.4
PEF (L/s) 5.4 ± 2.2 78.6 ± 25.5
TLC (L) 5.1 ± 1.4 91.6 ± 17.8
RV (L) 2.1 ± 0.6 113.8 ± 40.0
RV/TLC (%) 42.4 ± 8.2 123.7 ± 26.9
DLCO (mmol/min/kPa) 4.1 ± 1.6 53.0 ± 17.4
DLCO/VA (mmol/min/kPa/L) 1.0 ± 0.3 70.3 ± 21.7
PaCO2 (kPa) 4.9 ± 0.6 -
PaO2 (kPa) 9.8 ± 1.9 -
SpO2 (%) 96 ± 3 -
6MWD (m) 343 ± 103 64.8 ± 18.8
Values presented as means ± SD. FEV1 = forced expiratory volume during one
second; VC = vital capacity; FEF25–75 = forced expiratory flow between 25 %
and 75 % of vital capacity; PEF = peak expiratory flow; TLC = total lung
capacity; RV = residual volume; DLCO = diffusing capacity of the lung for
carbon monoxide; PaCO2 = arterial pressure of carbon dioxide; PaO2 =
arterial pressure of oxygen, SpO2 = oxygen saturation; 6MWD: Six-minute
walk distance.
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patients (10%) showed reduced TLC. A total of 23
patients presented signs of airway obstruction defined
as FEV1/VC < 0.70, while 15 patients showed FEV1/VC
< LLN. 27 patients had decreased FEV1 and 26 patients
had decreased PEF, defined as a value below 80% of the
predicted normal value. Two patients had reduced
oxygen saturation at rest (SpO2 < 90%).
Lung function indices and 6MWD in all subjects
In general, decreased lung function indices (<80% pre-
dicted) were associated with shorter 6MWD, as shown in
Figure 1. Twenty-four of the patients (48%) displayed air-
way obstruction, defined as FEV1/VC < 0.7, and patients
with FEV1/VC < 0.7 had a significantly shorter 6MWD
than patients without airway obstruction (307m vs. 377m,
p = 0.014) (Figure 1). These results were consistent when
airway obstruction was defined as value below LLN and
6MWDwas significantly lower in patients with FEV1/VC<
LLN than patients with FEV1/VC ≥ LLN (299m vs. 362m,
p = 0.046).
The strongest correlation with 6MWD was found for
PEF, followed by VC and FEV1 (Figure 2(a)). DLCO,
DLCO/VA, RV, SpO2 and arterial gases at rest did not
show any association with 6MWD. 6MWD was signifi-
cantly correlated toFEV1 (r
2 =0.15, p=0.01),VC (r2 =0.14,
p=0.02), PEF (r2=0.18, p=0.007) andFEV1/VC(r
2=0.16,
p = 0.01) after patients previously diagnosed with COPD
(n = 10) were excluded from the analyses.
Stepwise regression analysis in all PH subjects, in a
model where all lung function parameters (as absolute
values), arterial gases, gender, age, smoking habits and
BMI were included, yielded PEF as the sole determinant
of 6MWD (p = 0.002). A similar stepwise regression ana-
lysis, when lung functions were expressed as %predicted
instead, revealed PEF (%predicted) as the sole determinant
of 6MWD (p = 0.003). PEF remained the variable most
strongly associated with 6MWD also after adjusting for
gender, age, smoking habits, and BMI (Table 3).
Lung function indices and 6MWD in PH due to left
heart disease
Looking specifically at the largest group of PH patients, PH
group 2 (n = 27), the strongest relation to 6MWD was
foundwithRV/TLC (r2 =0.25), followedbyPEF (r2 =0.21),
p < 0.05 for both (Figure 2(b)). No significant correlations
of 6MWD with other lung function parameters were
found. Stepwise regression analysis in PH group 2, in a
model where all lung function parameters (as absolute
values), arterial gases, gender, age, smoking habits, and
BMI were included, yielded RV/TLC as the sole determi-
nant of 6MWD (p = 0.01).
The majority of the PH group 2 patients showed
FEV1/VC < 0.7 (56% of the subjects). The majority
of the patients in PH group 2 also displayed low
FEV1 (63% of the subjects) and low PEF (52% of
the subjects), both defined as a value below 80% of
Figure 1. Decreased lung function parameters in relation to 6MWD.
6MWD (m) in relation to decreased FEV1, PEF and VC (defined as <80% of predicted normal value) and FEV1/VC (defined as <0.70).
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predicted normal value. The finding of decreased
6MWD related to airway obstruction was also con-
sistent for PH group 2, as patients with FEV1/VC <
0.7 showed a significantly shorter 6MWD (305 m vs.
389 m, p = 0.03).
Lung function and exertional desaturation during
6MWT in all subjects
Twenty-two patients (44%) presented exertional desa-
turation following the 6MWT. Lower levels of DLCO/
VA, resting SpO2, FEV1/VC and PaO2 were significantly
Figure 2. Predictive value (expressed as r2) for 6MWD of single lung function measurements for all patients (a) and for PH due to
left heart disease (b).
Correlations (expressed as Pearson’s r2-values from simple linear regression models) between a patient’s six-minute walk distance and different
lung function parameters. (a) Only lung function parameters that were significantly correlated with 6MWD are shown. (b) * indicates significant
relation, p < 0.05.
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associated with exercise-induced oxygen desaturation
(Table 4). None of the lung volumes obtained through
the helium dilution technique showed a significant cor-
relation with exertional desaturation. Lower DLCO/VA
(OR 0.02, CI 0.001–0.4, p = 0.01), FEV1/VC-ratios (OR
0.92, CI 0.84–0.997, p = 0.04) and resting PaO2-values
(OR 0.95, CI 0.89–0.999, p = 0.04) remained significantly
correlated with desaturation also in a logistic regression
model adjusted for age, sex, BMI, and smoking habits.
After exclusion of COPD patients from above analyses,
lower DLCO/VA (OR 0.01, CI 0.0004–0.33, p = 0.009),
FEV1/VC-ratios (OR 0.90, CI 0.81–0.99, p = 0.04) and
resting SpO2-values (OR 0.67, CI 0.46–0.98, p = 0.04)
remained significantly correlated with desaturation in
the adjusted logistic regression model.
Stepwise regression analysis including all lung func-
tion parameters and arterial gases, gender, age, smok-
ing habits, and BMI revealed DLCO/VA as the main
determinant of oxygen desaturation during the 6MWT
(p = 0.01). Including only relative values in the step-
wise regression analysis, expressed as % predicted,
DLCO/VA (%predicted) was shown to be the main
determinant of exertional desaturation (p = 0.003).
Lung function and exertional desaturation during
6MWD in PH due to left heart disease
Investigating only PH group 2, 44% of the patients
(n = 12) displayed exertional desaturation. Lower levels
of DLCO/VA (p = 0.03) and resting SpO2 (p = 0.047)
were significantly associated with exercise-induced
oxygen desaturation in a single logistic regression
model. The relation to lower levels of DLCO/VA was
consistent after adjusting for age, sex, BMI, and smok-
ing habits (p = 0.04).
Discussion
The major finding of the present study was that airway
obstruction was strongly related to exercise capacity in
this group of unselected patients with PH.
Furthermore, this finding was consistent in a sub-ana-
lysis of patients with PH secondary to left heart disease,
the largest group included in the present material.
Diffusing capacity for carbon monoxide was not
related to exercise capacity, but related to oxygen desa-
turation during exercise. TLC measurements did not
provide any additional information in relation to the
studied outcomes, while RV/TLC-ratio was related to
exercise capacity.
Airway obstruction was related to a shorter six-minute
walk distance. This relation was consistent for different
expiratory lung function indices obtained through
dynamic spirometry (i.e. PEF, FEV1 and FEV1/VC) and
after adjustment for patient characteristics.
Previous studies have shown significant inspiratory
and expiratory muscle weakness in idiopathic pulmon-
ary arterial hypertension [19]. This could in fact mirror
the finding in our study, where PEF appeared to be the
variable most strongly associated with 6MWD.
Airway obstruction in PH has previously been studied
and 20–40% of the patients with PH group 1 have shown
airway obstruction based on a forced expiratory volume
in 1 sec to forced vital capacity ratio of less than 70%
[32,33]. Surprisingly, the association between airway
Table 3. Correlations between 6MWD and different lung func-










PEF (L/s) 0.19 0.001 0.01
VC (L) 0.18 0.002 0.01
FEV1 (L) 0.18 0.002 0.02
RV/TLC (%) 0.14 0.01 0.07
FEF25-75 (L) 0.12 0.01 0.051
TLC (L) 0.11 0.02 0.08
FEV1/VC (%) 0.08 0.050 0.04
DLCO (mmol/min/kPa) 0.06 0.10 0.25
PaCO2 (kPa) 0.02 0.36 0.23
SpO2 (%) 0.01 0.51 0.67
PaO2 (kPa) 0.01 0.52 0.48
RV (L) 0.01 0.47 0.69
DLCO/VA (mmol/min/kPa/L) < 0.01 0.86 0.89
* Adjusted for age, sex, BMI, and smoking habits.











1.1 (1.0–1.2) 0.9 (0.7–1.0) 0.003
Baseline SpO2 (%) 97.1 (96.4–97.9) 94.9 (92.9–96.8) 0.02
(%) 72.4 (69.3–75.4) 67.1 (62.5–71.6) 0.04
PaO2 (kPa) 10.3 (9.6–10.9) 9.2 (8.2–10.1) 0.047
DLCO (mmol/min/
kPa)
4.5 (3.8–5.1) 3.7 (3.0–0.9) 0.09
VC (L) 2.8 (2.5–3.1) 3.1 (2.6–3.6) 0.21
RV (L) 2.1 (1.8–2.3) 2.3 (2.0–2.6) 0.22
TLC (L) 4.9 (4.5–5.4) 5.4 (4.7–6.2) 0.22
PaCO2 (kPa) 5.0 (4.8–5.2) 4.8 (4.5–5.1) 0.29
FEF25-75 (L/s) 1.7 (1.4–2.0) 1.5 (1.0–1.9) 0.35
PEF (L/s) 5.2 (4.5–5.8) 5.7 (4.5–6.9) 0.39
FEV1 (L) 2.0 (1.8–2.2) 2.1 (1.8–2.5) 0.51
RV/TLC (%) 41.9 (38.7–45.2) 43.0 (39.2–46.7) 0.67
Values are presented as means (confidence interval) for patients who exhib-
ited exertional desaturation and patients without exercise-induced desatura-
tion. p-values pertain to the statistical outcomes of the t-tests between the
groups.
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obstruction and exercise capacity could also be seen in
patients with PH secondary to left heart failure, patients
who are more often regarded to be characterized by
restrictive lung function [34]. Moreover, in patients
with PH group 2, a relation with air trapping, assessed
through RV/TLC-ratio, was found which might reflect
lung congestion causing air trapping through peri-bron-
chial cuffs or lung stiffening [35]. One could argue the
fact that we speculate regarding air trapping as a potential
explanation when we use the RV- and TLC-values at rest,
as it is suggested that increasing lung hyperinflation dur-
ing exercise (dynamic hyperinflation) is more closely
related to exercise intolerance and clinical dyspnoea
than airflow limitation and static hyperinflation [36].
We hypothesized in advance that DLCO would have a
large impact on exertional desaturation in patients suffer-
ing from PH [37]. However, in the present material, an
unexpected significant association was found between
FEV1/VC and exercise-induced desaturation.
No relation between diffusing capacity for carbon
monoxide and walk distance was found in the present
material. The diffusing capacity relates inversely to the
mean pulmonary arterial pressure and this is in line
with results from echocardiography studies, which
found no relation between pulmonary arterial pressure
and 6MWD [20]. We hypothesize that the patients
were characterized as pulmonary hypertensive, e.g.
reduced diffusion capacity, makes airway obstruction
more influential in the outcome of 6MWT due to a
tendency of uniformity for DLCO. This is in fact in line
with previous findings from our group in which we
could demonstrate that in patients suffering from
COPD, e.g. airway obstruction, DLCO is more closely
linked to reduced walk distance [38]. On the other
hand, DLCO/VA was revealed as the main determinant
of exercise-induced desaturation, which is in line with
reported interdependence between pulmonary diffu-
sion and oxygen desaturation during exercise in
patients with diffuse systemic sclerosis and interstitial
lung disease [39].
Total lung capacity measurements obtained through
the hilum dilution technique did not offer supplementary
information. This is in accordance with previous studies
where lung volume measurements offered minimal addi-
tional information [40–42]. In a study by Armstrong et al.
[40], the authors were unable to show any relationship
between peak exercise capacity and lung volumes in
patients suffering from interstitial pulmonary disease
with or without pulmonary hypertension.
The strength of the study is the availability of extensive
lung function characterization. However, the study has its
limitations as it was a single centre investigation with a
relatively low total number of study subjects. This limited
the possibilities of performing sub-analyses with regard to
type of PH, with the exception of PH group 2, the largest
group investigated, where we confirmed the main finding
of the present study regarding the relation between airway
obstruction and exercise capacity. It could be argued that
the term airway obstruction was used quite broadly, and
lower PEF or FEV1 might be due to other underlying
pathologies, such as decreased respiratory muscle strength
or a pulmonary restrictive component. However, the find-
ings were confirmed when airway obstruction was defined
as FEV1/VC-ratio (less than 0.7) and a restrictive pattern
was seen in only a minority (10%) of the subjects. Another
point of argue could be that not all study patients per-
formed lung function testing similarly and mandatory
post-bronchodilatory spirometry was carried out only in
patients with previously known COPD diagnosis (n = 10).
However, we believe that this approach mirrors the func-
tional capacity in COPD patients in a more suitable man-
ner. As patients with COPD are treated with
bronchodilator medication, post-bronchodilatory lung
function would display their baseline status before
6MWT more accurately, as the patients in other disease
categories do not use bronchodilators.Moreover, ourmain
findings were consistent even after exclusion of COPD
patients. Unfortunately, we lack more detailed data on
smoking history and therefore could not account for this
in the regression models. Another limitation of the present
study is that no assessment of peripheral muscle function
was done, for example muscle strength, as peripheral mus-
cle dysfunction is common in PH and relates with reduced
exercise capacity [43]. Another major limitation of the
study is the lack of current data on pulmonary arterial
pressure as PH-diagnosis was made at a previous and
variable time compared with the investigation of lung
function and 6MWD. Although PH is a clinical syndrome
with different underlying etiology, the key diagnostic fea-
ture is an elevated pulmonary artery pressure [44].
Nevertheless, functional parameters such as NYHA class
and 6-min walk distance have a prognostic significance
superior to most standard resting haemodynamic para-
meters despite underlying causes of disease [20,45].
However, whilst it is widely accepted that exercise capacity
in patients with pulmonary hypertension is limited by
cardiac output, the impact of pulmonary function has not
been fully investigated.
Conclusion
Airway obstruction was an important predictor of walk
distance and exercise-induced desaturation in this unse-
lected material of PH patients with a very low prevalence
of PH secondary to lung disease and this finding was
consistent after exclusion of subjects with COPD. As
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6MWD is an important predictor of mortality in PH
patients, it is important to better understand the limita-
tions of 6MWD in individual PH patients, as obstruction
is probably independent of PH in most of these patients.
The obstructive component that could be identified this
way might be a treatable target and therefore it would be
clinically useful to map this pulmonary function compo-
nent in PH patients.
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